Page 34 - CL Armchair Case

PROXYDYCHROMIL

Proxydychromil had been in development for over nine

years and had cost in excess of £250m to bring it to the

market. It had passed all clinical trials in Europe and the USA

and was poised to be the company’s premier product.

Its value lay in that it not only alleviated the symptoms of

asthma, but it also helped develop prolonged resistance to

recurring episodes.

Michael Blackthorn was in his office when he received an

urgent request from his chief research officer for an

immediate meeting.

Some twenty minutes later Kline, the CRO arrived and

turned Blackthorn’s life upside down by posing a moral

dilemma that would challenge him both as a man and as a

corporate executive.